Shkodra, B.; Press, A.T.; Vollrath, A.; Nischang, I.; Schubert, S.; Hoeppener, S.; Haas, D.; Enzensperger, C.; Lehmann, M.; Babic, P.;
et al. Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I. Pharmaceutics 2020, 12, 1110.
https://doi.org/10.3390/pharmaceutics12111110
AMA Style
Shkodra B, Press AT, Vollrath A, Nischang I, Schubert S, Hoeppener S, Haas D, Enzensperger C, Lehmann M, Babic P,
et al. Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I. Pharmaceutics. 2020; 12(11):1110.
https://doi.org/10.3390/pharmaceutics12111110
Chicago/Turabian Style
Shkodra, Blerina, Adrian T. Press, Antje Vollrath, Ivo Nischang, Stephanie Schubert, Stephanie Hoeppener, Dorothee Haas, Christoph Enzensperger, Marc Lehmann, Petra Babic,
and et al. 2020. "Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I" Pharmaceutics 12, no. 11: 1110.
https://doi.org/10.3390/pharmaceutics12111110
APA Style
Shkodra, B., Press, A. T., Vollrath, A., Nischang, I., Schubert, S., Hoeppener, S., Haas, D., Enzensperger, C., Lehmann, M., Babic, P., Benecke, K. J., Traeger, A., Bauer, M., & Schubert, U. S.
(2020). Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I. Pharmaceutics, 12(11), 1110.
https://doi.org/10.3390/pharmaceutics12111110